ST Pharm

Seoul, South Korea
Find alternatives to ST Pharm for Oligonucleotide →
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
59.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (18) ○ EMA GMP ○ MHRA GMP

Quick Facts: ST Pharm

Signal Score
59.0/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
Seoul, South Korea
Modalities
Oligonucleotide, mRNA
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About ST Pharm

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesOligonucleotide, mRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
1 manufacturing site: Seoul, KR
Modalities: Oligonucleotide, mRNA
Capacity assessment: 58.0/100
Sites: Seoul, KR
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals18 articles (not scored)
1 manufacturing site: Seoul, KR
Modalities: Oligonucleotide, mRNA
Capacity assessment: 58.0/100

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source: public careers pages · Checked Nov 20, 2026

Company Signals 18 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-10-27
Dong-A ST and ST Pharm log Q3 sales, profit gains in South Korea - Chosunbiz
Dong-A ST and ST Pharm log Q3 sales, profit gains in South Korea  Chosunbiz
general 2026-10-22
ST Pharm, Which Received Equipment and Technology Support from Roche, Sets Sights on Major RNA Contract Manufacturing Orders - BigGo Finance
ST Pharm, Which Received Equipment and Technology Support from Roche, Sets Sights on Major RNA Contract Manufacturing Orders  BigGo Finance
general 2026-10-22
Roche ties help Korea’s ST Pharm pursue major RNA CDMO wins - Chosunbiz
Roche ties help Korea’s ST Pharm pursue major RNA CDMO wins  Chosunbiz
capacity 2026-10-08
ST Pharm pitches expanded oligonucleotide capacity to global drugmakers at CPHI - Korea Biomedical Review
ST Pharm pitches expanded oligonucleotide capacity to global drugmakers at CPHI  Korea Biomedical Review
general 2026-10-08
ST Pharm Seeks New Oligonucleotide CDMO Contracts at CPHI 2026 - 아시아경제
ST Pharm Seeks New Oligonucleotide CDMO Contracts at CPHI 2026  아시아경제
financial 2026-04-28
ST Pharm First-Quarter Operating Profit Surges Tenfold - thelec.net
ST Pharm First-Quarter Operating Profit Surges Tenfold  thelec.net
general 2026-04-27
Dong-A group's Q1 sales rise as ST Pharm, Dong-A ST profits climb - koreabiomed.com
Dong-A group's Q1 sales rise as ST Pharm, Dong-A ST profits climb  koreabiomed.com
general 2026-04-13
ST Pharm Secures Japanese Patent for Key LNP Material 'STP1244' - 아시아경제
ST Pharm Secures Japanese Patent for Key LNP Material 'STP1244' - The Asia Business Daily  아시아경제
general 2026-03-31
ST Pharm Poised for Order Surge as RNA Therapeutics Market Expands - 서울경제신문
ST Pharm Poised for Order Surge as RNA Therapeutics Market Expands  Seoul Economic Daily
general 2026-03-31
ST Pharm Poised for Order Surge as RNA Therapeutics Market Expands - Seoul Economic Daily
ST Pharm Poised for Order Surge as RNA Therapeutics Market Expands  Seoul Economic Daily
general 2026-03-17
ST Pharm Signs Record 89.7 Billion Won Oligonucleotide Contract - Businesskorea
ST Pharm Signs Record 89.7 Billion Won Oligonucleotide Contract  Businesskorea
general 2026-03-17
ST Pharm lands record-breaking single CMO order worth KRW 89.7 billion from global pharmaceutical giant - 더바이오
ST Pharm lands record-breaking single CMO order worth KRW 89.7 billion from global pharmaceutical giant  더바이오
general 2026-03-16
ST Pharm secures record oligo API deal with European drugmaker - CHOSUNBIZ - Chosunbiz
ST Pharm secures record oligo API deal with European drugmaker - CHOSUNBIZ  Chosunbiz
general 2026-03-16
ST Pharm Signs KRW 89.7 Billion Oligonucleotide Order, Largest Single Contract to Date - 아시아경제
ST Pharm Signs KRW 89.7 Billion Oligonucleotide Order, Largest Single Contract to Date  아시아경제
general 2026-03-06
ST Pharm to produce non-clinical samples for Nipah virus mRNA vaccine - koreabiomed.com
ST Pharm to produce non-clinical samples for Nipah virus mRNA vaccine  koreabiomed.com
general 2026-03-06
ST Pharm Begins Production of Nipah Virus mRNA Vaccine Samples - 아시아경제
ST Pharm Begins Production of Nipah Virus mRNA Vaccine Samples  아시아경제
general 2026-03-06
ST Pharm begins Nipah mRNA vaccine preclinical production in South Korea - CHOSUNBIZ - Chosunbiz
ST Pharm begins Nipah mRNA vaccine preclinical production in South Korea - CHOSUNBIZ  biz.chosun.com
capacity 2026-03-05
Korea’s pharma ramps up capacity to win global orders amid pricing shifts - CHOSUNBIZ - biz.chosun.com
Korea’s pharma ramps up capacity to win global orders amid pricing shifts - CHOSUNBIZ  Chosunbiz

Frequently Asked Questions About ST Pharm

What is ST Pharm's CDMO Signal Score?
ST Pharm has a Signal Score of 59/100, based on quality, operations, financial stability, and capacity data.
Evaluating ST Pharm for a manufacturing program?
Use the free AI matchmaker to compare ST Pharm against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Oligonucleotide CDMOs → mRNA CDMOs →

Similar CDMOs

Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
Kaneka Eurogentec
Seraing, BE
Signal Score: 81.6
mRNA, Plasmid, Oligonucleotide
Nitto Denko Avecia
Milford, MA
Signal Score: 80.3
Oligonucleotide, mRNA
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
Signal Score: 79.5
mRNA, Oligonucleotide, Biologics
TriLink BioTechnologies
San Diego, CA
Signal Score: 63.0
mRNA, Oligonucleotide

Compare ST Pharm with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on ST Pharm
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.